Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks?
Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Exelixis's Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. EXEL plans to diversify its oncology portfolio by launching one new indication for Zanzalintinib annually. Zanzalintinib could also grow into a $5 billion yearly revenue asset by 2033, potentially surpassing Cabometyx as Exelixis's primary revenue source. The company has repurchased $462.4 million in shares this year, showcasing it's a shareholder-friendly company as well.
Exelixis Beats on Q3 Earnings and Sales, Raises Annual Outlook
EXEL tops on earnings and sales in the third quarter as lead drug Cabometyx maintains momentum. The company also raises its revenue guidance for 2024.
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner - EVP & CFO Amy Peterson - EVP, Product Development, Medical Affairs & Chief Medical Officer Dana Aftab - Chief Scientific Officer P.J. Haley - EVP, Commercial Conference Call Participants Asthika Goonewardene - Truist Chi Fong - Bank of America Silvan Tuerkcan - Citizens JMP Michael Schmidt - Guggenheim Securities Gregory Renza - RBC Capital Markets Yaron Werber - TD Cowen Jay Olson - Oppenheimer Andy Hsieh - William Blair Ashwani Verma - UBS Peter Lawson - Barclays Lukas Shumway - BMO Capital Markets Sudan Loganathan - Stephens Chris Shibutani - Goldman Sachs Joseph Catanzaro - Piper Sandler Operator Good day, ladies and gentlemen, and welcome to Exelixis Third Quarter 2024 Financial Results Conference Call.
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
